Skip to content

News

Organization Information

3920 Point Eden Way
Hayward CA 94545
Phone: (510) 723-4000
Fax: (510) 723-4699

www.novonordisk.com

Ownership: Public
Stock Symbol: NVO
Revenue: $2,502m

Our Leadership

  • Jerzy Gruhn, President
  • Steve McGill, Director, Government Affairs
  • Tom Boyer, Director of Government Affairs
  • Lars Rebien Sorenson, President and CEO
Founded: 1992
Region: Sacramento , Washington DC
Total Employees: 22000
Organization Type: Biotech, Pharmaceutical

Novo Nordisk Inc.

Organization Profile

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.

Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

With headquarters in Denmark, Novo Nordisk employs approximately 22,000 full-time employees in 79 countries, and markets its products in 179 countries.

Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.

Disease Focus

Diabetes , Hormone replacement (misc)